SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo
📖

Alzheimer's Disease vs Parkinson's Disease Comparison

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-alzheimers-parkinsons-comp
Related Entities
diseases-alzheimers-parkinsons-comparison
Metadata
slugdiseases-alzheimers-parkinsons-comparison
entity_typedisease
kg_node_idNone
Linked Artifacts (722)
mentions🧪Gamma entrainment therapy to restore hippocampal-cortical sy80%
related🧪HSP90-Tau Disaggregation Complex Enhancement80%
related🧪VCP-Mediated Autophagy Enhancement80%
related🧪LRP1-Dependent Tau Uptake Disruption80%
related🧪Extracellular Vesicle Biogenesis Modulation80%
related🧪Synaptic Vesicle Tau Capture Inhibition80%
related🧪TREM2-mediated microglial tau clearance enhancement80%
related🧪Trans-Synaptic Adhesion Molecule Modulation80%
related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia80%
related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation80%
related🧪Complement C1QA Spatial Gradient in Cortical Layers80%
related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation80%
related🧪APOE Isoform Expression Across Glial Subtypes80%
related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro80%
related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli80%
related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK80%
related🧪Prefrontal sensory gating circuit restoration via PV interne80%
related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna80%
related🧪Gamma entrainment therapy to restore hippocampal-cortical sy80%
see_also📖Alzheimer's Disease Biomarkers80%
see_also📖ASL Perfusion Biomarkers for Alzheimer's Disease80%
see_also📖Digital Biomarkers for Alzheimer's Disease80%
see_also📖Dried Blood Spot Biomarker Test for Alzheimer's Disease80%
see_also📖DTI Biomarkers for Alzheimer's Disease80%
see_also📖EEG Biomarkers for Alzheimer's Disease80%
see_also📖Eye-Tracking Digital Markers in Alzheimer's Disease80%
see_also📖Gait Biomarkers for Alzheimer's Disease80%
see_also📖GFAP in Alzheimer's Disease80%
see_also📖Inflammatory Biomarkers in Alzheimer's Disease80%
see_also📖Neurogranin - Alzheimer's Disease Biomarker80%
see_also📖NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease80%
see_also📖Ocular Fluid Biomarkers for Alzheimer's Disease80%
see_also📖Olfactory Biomarkers for Alzheimer's Disease80%
see_also📖Plasma Phospho-Tau Ratio Diagnostic Panel for Alzheimer'80%
see_also📖Salivary Biomarkers for Alzheimer's Disease80%
see_also📖Sleep Biomarkers for Alzheimer's Disease80%
see_also📖Speech and Cognitive Biomarkers for Alzheimer's Disease80%
see_also📖Synaptic Biomarkers for Alzheimer's Disease80%
see_also📖Tear Film Biomarkers in Alzheimer's Disease80%
see_also📖VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers80%
see_also📖Diffuse Amyloid Deposits in Alzheimer's Disease80%
see_also📖ACP-204 for Alzheimer's Disease Psychosis (NCT06159673)80%
see_also📖Adipose-Derived Mesenchymal Stem Cell Therapy for Early Alzh80%
see_also📖ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT05680%
see_also📖BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer80%
see_also📖BMS-986368 Phase 2 - Agitation in Alzheimer's Disease80%
see_also📖BMS-986446 Phase 2 Trial for Early Alzheimer's Disease80%
see_also📖Cannabidiol for Alzheimer's Disease Prevention (NCT058280%
see_also📖Centella asiatica Phase 1 Trial for Alzheimer's Disease80%
see_also📖EI-1071 Immunomodulator for Alzheimer's Disease (NCT06780%
see_also📖Escitalopram for Agitation in Alzheimer's Disease (NCT080%
see_also📖EX039 Phase 2 (NCT05413655) — Oral Therapeutic for Alzheimer80%
see_also📖ExPlas — Exercise Plasma Transfusion for Alzheimer's Di80%
see_also📖Fasudil for Early Alzheimer's Disease (FEAD) - NCT0636280%
see_also📖[F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disea80%
see_also📖Foralumab Phase 2 Trial for Alzheimer's Disease80%
see_also📖GSK4527226 (AL101) for Early Alzheimer's Disease (NCT0680%
see_also📖Guanfacine NorAD - Phase 3 Trial for Alzheimer's Diseas80%
see_also📖IGC-AD1 for Agitation in Alzheimer's Disease (NCT05543680%
see_also📖ITI-1284 for Alzheimer's Disease Psychosis (NCT0654083380%
see_also📖KarXT (Xanomeline/Trospium) - Phase 3 for Alzheimer's D80%
see_also📖Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Dise80%
see_also📖LEAF Trial - THC+CBD for Alzheimer's Disease Agitation 80%
see_also📖NCT03875638 - Levetiracetam for Alzheimer's Disease80%
see_also📖NCT07477431 - Levetiracetam for Persons at Risk for Alzheime80%
see_also📖LHP588: P. gingivalis Targeting for Alzheimer's Disease80%
see_also📖MAR Polypill for Alzheimer's Disease (NCT06597058)80%
see_also📖Masupirdine for Alzheimer's Disease Agitation80%
see_also📖Masupirdine for Agitation in Alzheimer's Disease (NCT0580%
see_also📖MK-2214 for Early Alzheimer's Disease80%
see_also📖Nabilone for Agitation in Alzheimer's Disease (NCT0451680%
see_also📖NAB-IT: Nabilone for Agitation in Alzheimer's Disease80%
see_also📖TRAILBLAZER-ALZ 3 (NCT05026866) — Donanemab for Preclinical 80%
see_also📖GV1001 for Moderate to Severe Alzheimer's Disease (NCT080%
see_also📖Biogen Alzheimer's Disease Phase 2 Trial (NCT05399888)80%
see_also📖TRAILRUNNER-ALZ 1: Remternetug for Early Alzheimer's Di80%
see_also📖Synaptic Therapy Alzheimer's Research Trial (START): A 80%
see_also📖CBD (Cannabidiol) for Alzheimer's Disease Agitation - N80%
see_also📖GSK4527226 (AL101) for Early Alzheimer's Disease (NCT0680%
see_also📖The Alzheimer's Disease Tau Platform Clinical Trial (NC80%
see_also📖KarXT for Alzheimer's Disease Cognitive Impairment - MI80%
see_also📖KarXT for Alzheimer's Disease Cognitive Impairment - MI80%
see_also📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St80%
see_also📖Novartis Alzheimer's Disease Phase 2 Trial (NCT0709451680%
see_also📖Master Screening Study to Determine Individuals With Potenti80%
see_also📖NRTIs for Alzheimer's Disease - Phase 1 (NCT07210528)80%
see_also📖X/T + X-EC + Lecanemab Phase 2 (NCT07212062) — Alzheimer80%
see_also📖DMB-I (Latrepirdine) Phase 3 (NCT07251023) — Alzheimer'80%
see_also📖Exciva Alzheimer's Disease Phase 2/3 Trial80%
see_also📖NCT06582706: Nicotinic Acid for Alzheimer's Disease80%
see_also📖NCT07262645: Near-Infrared Light Therapy for Mild-Moderate A80%
see_also📖NRTIs for Alzheimer's Disease: Targeting Type-I Interfe80%
see_also📖ONO-2020 for Alzheimer's Disease (NCT06881836)80%
see_also📖NCT06803823 - ONO-2020 for Agitation in Alzheimer's Dis80%
see_also📖Ozanimod for Alzheimer's Disease (NCT06862960)80%
see_also📖Piromelatine 20 mg for Mild Dementia Due to Alzheimer's80%
see_also📖PLX5622 CSF1R Inhibitor Trial in Early Alzheimer's Dise80%
see_also📖Probiotics in Mild Alzheimer's Disease (NCT06181513)80%
see_also📖Recombinant Human Serum Albumin for Alzheimer's Disease80%
see_also📖Rotigotine and Rivastigmine Combination Therapy for Alzheime80%
see_also📖Senicapoc Alzheimer's Disease Trial - NCT0480424180%
see_also📖SHR-1707 for Alzheimer's Disease (NCT06199037)80%
see_also📖Siponimod for Alzheimer's Disease (NCT06639282)80%
see_also📖SNIFF-Combo: Intranasal Insulin + Empagliflozin for Alzheime80%
see_also📖SToP-AD: Suvorexant for Alzheimer's Disease Prevention80%
see_also📖TRAP-AD: Transcranial Photobiomodulation for Alzheimer'80%
see_also📖VY7523 Phase 1/2 Alzheimer's Disease Trial80%
see_also📖Alzheimer's Disease Mechanism Index80%
see_also📖APOE Lipid Metabolism Pathway in Alzheimer's Disease80%
see_also📖APOE4 and Alzheimer's Disease Risk80%
see_also📖CD33 Siglec Receptor Dysfunction Alzheimer's Disease Ca80%
see_also📖Cholinergic System Degeneration in Alzheimer's Disease80%
see_also📖EEG Microstates in Alzheimer's Disease80%
see_also📖Endolysosomal Pathway in Alzheimer's Disease80%
see_also📖Geniposide for Alzheimer's disease - immune biomarker t80%
see_also📖Glymphatic System in Alzheimer's Disease80%
see_also📖Locus Coeruleus Degeneration in Alzheimer's Disease80%
see_also📖Metal Ion Homeostasis in Alzheimer's Disease80%
see_also📖Mitochondrial Dysfunction in Alzheimer's Disease Pathwa80%
see_also📖Neuroinflammation in Alzheimer's Disease80%
see_also📖Neuroinflammation Hypothesis in Alzheimer's Disease80%
see_also📖Neurovascular Dysfunction in Alzheimer's Disease: Integ80%
see_also📖NLRP3 Inflammasome Pathway in Alzheimer's Disease80%
see_also📖Sex-Specific Mechanisms in Alzheimer's Disease80%
see_also📖Sleep and Circadian Dysfunction in Alzheimer's Disease80%
see_also📖Sporadic Alzheimer's Disease Pathway80%
see_also📖Synaptic Loss in Alzheimer's Disease Pathway80%
see_also📖Tau Kinase-Phosphatase Balance in Alzheimer's Disease80%
see_also📖Tau Kinase Signaling Cascade in Alzheimer's Disease80%
see_also📖Ubiquitin-Proteasome System Dysfunction in Alzheimer's 80%
see_also📖Vascular Dementia Mechanisms — Overlap with Alzheimer's80%
mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna79%
mentions🧪Prefrontal sensory gating circuit restoration via PV interne78%
related🧪Gamma entrainment therapy to restore hippocampal-cortical sy72%
related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro72%
related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli72%
related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK72%
related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna71%
related🧪Prefrontal sensory gating circuit restoration via PV interne71%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
mentions🧫Endothelial CD2AP knockdown effects on memory in male mice60%
mentions🧫SPP1-mediated microglial synaptic engulfment assay60%
mentions🧫CD2AP expression and cognitive decline in AD patients60%
mentions🧫Competing endogenous RNA (ceRNA) network construction60%
mentions🧫Neuroimmune modulation and Aβ clearance mechanisms60%
mentions🧫GWAS of plasma NfL in East Asian cohort60%
mentions🧫Bioinformatics analysis and hub gene identification60%
mentions🧫Network Pharmacology Analysis of Shared AD Targets60%
mentions🧫Cognitive impact of TDP-43 pathology in AD patients60%
mentions🧫Meta-analysis of LRP1 C766T polymorphism and Alzheimer'60%
mentions🧫GWAS of composite biomarker score60%
mentions🧫MRI Phenotyping Method Concordance in Serbian AD Cohort60%
mentions🧫HDAC4 inhibition and NHE6 expression mechanism study60%
mentions🧫Endothelin-1 receptor A antagonist rescue in male CD2AP mice60%
mentions🧫Endothelin-1 receptor A antagonist rescue experiment60%
mentions🧫Reelin treatment rescue via ApoER2 in CD2AP mutant mice60%
mentions🧫SPP1 upregulation in perivascular cells in AD mouse models60%
mentions🧫Amyloid plaque load analysis in triple-mutant mouse brains60%
mentions🧫Plasma ATN biomarkers across AD continuum in Chilean cohort60%
mentions🧫16S rRNA sequencing of gut microbiome in PH-PS treated mice60%
mentions🧫GWAS of plasma pTau217 in East Asian cohort60%
mentions🧫PH-PS treatment in 5×FAD Alzheimer's disease mice60%
mentions🧫SIRPα modulation in mouse models of Alzheimer's disease60%
mentions🧫Dairy intake and dementia risk in Malmö Diet and Cancer coho60%
mentions🧫Spp1 knockout prevents synaptic loss in AD mouse models60%
mentions🧫Creation and validation of 3xAD-ChAT-Cre mouse model60%
mentions🧫In vivo BBB transport of LPS-carrying bEVs60%
mentions🧫Real-world safety study of Lecanemab in Japanese AD patients60%
mentions🧫CHI3L1 variant association with AD progression in human pati60%
mentions🧫Diosmin cognitive rescue in APP/PS1 mice60%
mentions🧫GWAS of plasma pTau181 in East Asian cohort60%
mentions🧫Tet2 modulation in Aβ42-injured mouse hippocampal neurons60%
mentions🧫Behavioral assessment of APP/PSEN1/GD3S triple-mutant mice60%
mentions🧫Immunofluorescence analysis of cerebral microvascular densit60%
mentions🧫Cell-cell interaction analysis of perivascular-microglial cr60%
mentions🧫SAHA@LIPO-ANG2 therapeutic efficacy in 5xFAD mice60%
mentions🧫Adoptive transfer of TCRAβ-Tregs in AD mouse model60%
mentions🧫Chi3l1 deletion in APP/PS1 mouse model of Alzheimer's d60%
mentions🧫CD2AP downregulation in brain endothelial cells - memory fun60%
mentions🧫Transcriptomic profiling and differential expression analysi60%
mentions🧫AAV-mediated Tet2 modulation in 2×Tg-AD mice behavioral stud60%
mentions🧫Single-cell RNA sequencing of microglial states in AD hippoc60%
mentions🧫bEV-mediated synaptic pruning via C1q-C3 pathway60%
mentions🧫AhR agonist effects on NEP expression in N2a cells60%
mentions🧫AhR transcriptional regulation of NEP gene60%
mentions🧫GWAS of plasma GFAP in East Asian cohort60%
mentions🧫AhR agonist effects on NEP in APP/PS1 mice60%
mentions🧫Abeta-induced cell death and aggregation in GD3S-deficient n60%
mentions🧫bEV isolation and LPS quantification from human samples60%
mentions🧫Cerebral blood flow regulation in CD2AP mutant mice60%
mentions🧫Meta-analysis of physical activity interventions on cognitiv60%
mentions🧫Single-nucleus RNA-seq integration analysis60%
mentions🧫Generation of Aβ-specific Tregs using CRISPR-Cas960%
mentions🧫qPCR and western blot analysis of microvascular functional m60%
mentions🧫Reelin glycoprotein treatment rescue experiment60%
mentions🧫bEV extraction and analysis from mouse samples60%
mentions🧫KEEPS Continuation: Long-term effects of menopausal hormone 60%
mentions🧫Summary-based Mendelian randomization analysis60%
mentions🧫Anti-ASC antibody intracerebroventricular injection in APP/P60%
mentions🧫ASC antibody treatment in SH-SY5Y-APP695 cells60%
mentions🧫Tet2 expression analysis in aged 2×Tg-AD mouse brains60%
mentions🧫Morphological characterization of microglial states in human60%
mentions🧫Microglial SIRPα expression in human Alzheimer's diseas60%
mentions🧫APOE4 association with TDP-43 pathology in AD60%
mentions🧫Microglial activation by bEVs via Piezo160%
mentions🧫Curcumin-Licorice Combination in D-galactose/Sodium Nitrite 60%
mentions🧫Cerebrovascular function analysis in CD2AP mutant mice60%
mentions🧫CD2AP loss association with cognitive decline in AD patients60%
mentions🧫TDP-43 pathology prevalence and distribution in AD cases60%
mentions🧪Complement C1QA Spatial Gradient in Cortical Layers60%
mentions🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro60%
mentions🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK60%
mentions🧫Longitudinal TLR2 reporter gene study in α-synuclein mice60%
mentions🧫iPSC-derived astrocyte-neuron co-culture mitochondrial trans60%
mentions🧫TLR expression in α-synuclein overexpressing mice60%
mentions🧫TLR expression analysis in Parkinson's disease patients60%
mentions🧫Dexamethasone treatment study in α-synuclein mice60%
mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia60%
mentions🧪GFAP-Positive Reactive Astrocyte Subtype Delineation60%
mentions🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation60%
mentions🧪APOE Isoform Expression Across Glial Subtypes60%
mentions🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli60%
related🧫s:** - Test whether HCN1 knockout specifically in EC layer I60%
related🧫Proposed experiment from debate on Synaptic pruning by micro60%
related🧫Brain Connectivity-Targeted tACS Trial in Early AD60%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%
related🧫4R-Tau Targeting Therapies for PSP and CBS60%
related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi60%
related🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau60%
related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti60%
related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?60%
related🧫Animal Model Comparison for Neurodegenerative Disease Therap60%
related🧫Anti-Tau Immunotherapy Dosing Optimization60%
related🧫ApoE4 Function in Alzheimer's Disease60%
related🧫Experiment: Autoimmune Hypothesis Testing in AD60%
related🧫Autophagy Enhancement Drug Screening for Neurodegeneration60%
related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#60%
related🧫Blood-Based Biomarker Panel for Early AD Detection60%
related🧫tACS Connectivity Trial in Early Alzheimer's60%
related🧫Brain Connectivity-Targeted tACS Trial in Early AD60%
related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 60%
related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M60%
related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera60%
related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera60%
related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa60%
related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation60%
related🧫Gap Junction Dysfunction Validation in Parkinson's Dise60%
related🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas60%
related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise60%
related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech60%
related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr60%
related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis60%
related🧫Mixed Pathology Effects on Parkinson's Disease Progress60%
related🧫Neural Stem Cell Therapy for Alzheimer's Disease60%
related🧫Normal Aging to Alzheimer's Disease Transition Trigger 60%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%
related🧫Prion Strain Diversity and Selective Vulnerability60%
related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease60%
related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#60%
related🧫Sex Differences in Alzheimer's Disease — mechanisms and60%
related🧫Sleep Disruption and Alzheimer's Disease — mechanism an60%
related🧫Traumatic Brain Injury and Alzheimer's Disease Relation60%
related🧫Experiment Validation: In vitro ThT Assay60%
related🧫Tau ASO Therapy60%
related🧫Microglial TREM2 Agonist In Vivo Efficacy60%
related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia60%
related🧫Vascular Contribution to Alzheimer's Disease — Beyond A60%
related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol60%
related🧫Viral Infections and Alzheimer's Disease — causal mecha60%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera60%
related🧫AAV-LRRK2 IND-Enabling Study Design60%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD60%
related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back60%
related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio60%
related🧫Computational Modeling of Alpha-Synuclein Propagation in PD60%
related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation60%
related🧫Alpha-Synuclein Seed Amplification Assay Validation60%
related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation60%
related🧫Antiviral Therapy Trial for Parkinson's Disease60%
related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&60%
related🧫Axonal Transport Dysfunction Validation in Parkinson's 60%
related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise60%
related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 60%
related🧫Combination Therapy Sequencing in Parkinson's Disease60%
related🧫CRISPR Gene Correction Approaches for CBS/PSP60%
related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa60%
related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#60%
related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i60%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#60%
related🧫Epigenetic Dysregulation Validation in Parkinson's Dise60%
related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD60%
related🧫Ferroptosis Validation in Parkinson's Disease60%
related🧫GLP-1 Agonist Neuroprotection Mechanism in PD60%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&60%
related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me60%
related🧫Cytochrome Therapeutics60%
related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson60%
related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown60%
related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design60%
related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne60%
related🧫Macroautophagy Dysfunction in PD - Experiment Design60%
related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P60%
related🧫Validation: Membrane-Nucleation in iPSC Neurons60%
related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr60%
related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 60%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag60%
related🧫MLCS Quantification in Parkinson's Disease60%
related🧫Experiment: Multi-Ethnic PD GWAS60%
related🧫Multiscale Computational Modeling of Protein Aggregation Kin60%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'60%
related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise60%
related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper60%
related🧫Non-Motor Symptom Progression in Parkinson's Disease — 60%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#60%
related🧫Parkinson's Disease Subtype Classification — Precision 60%
related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea60%
related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas60%
related🧫Prodromal Parkinson's Disease Biomarker Development — E60%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin60%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson60%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise60%
related🧫Sirtuin Dysfunction Validation in Parkinson's Disease60%
related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D60%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di60%
related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&60%
related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki60%
related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim60%
mentions🧫s:** - Test whether HCN1 knockout specifically in EC layer I55%
mentions🧫Proposed experiment from debate on Synaptic pruning by micro55%
mentions🧫Brain Connectivity-Targeted tACS Trial in Early AD55%
mentions🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 55%
mentions🧫4R-Tau Targeting Therapies for PSP and CBS55%
mentions🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi55%
mentions🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau55%
mentions🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti55%
mentions🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?55%
mentions🧫Animal Model Comparison for Neurodegenerative Disease Therap55%
mentions🧫Anti-Tau Immunotherapy Dosing Optimization55%
mentions🧫ApoE4 Function in Alzheimer's Disease55%
mentions🧫Experiment: Autoimmune Hypothesis Testing in AD55%
mentions🧫Autophagy Enhancement Drug Screening for Neurodegeneration55%
mentions🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#55%
mentions🧫Blood-Based Biomarker Panel for Early AD Detection55%
mentions🧫tACS Connectivity Trial in Early Alzheimer's55%
mentions🧫Brain Connectivity-Targeted tACS Trial in Early AD55%
mentions🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 55%
mentions🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M55%
mentions🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera55%
mentions🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera55%
mentions🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa55%
mentions🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation55%
mentions🧫Gap Junction Dysfunction Validation in Parkinson's Dise55%
mentions🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas55%
mentions🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise55%
mentions🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech55%
mentions🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr55%
mentions🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis55%
mentions🧫Mixed Pathology Effects on Parkinson's Disease Progress55%
mentions🧫Neural Stem Cell Therapy for Alzheimer's Disease55%
mentions🧫Normal Aging to Alzheimer's Disease Transition Trigger 55%
mentions🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 55%
mentions🧫Prion Strain Diversity and Selective Vulnerability55%
mentions🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease55%
mentions🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#55%
mentions🧫Sex Differences in Alzheimer's Disease — mechanisms and55%
mentions🧫Sleep Disruption and Alzheimer's Disease — mechanism an55%
mentions🧫Traumatic Brain Injury and Alzheimer's Disease Relation55%
mentions🧫Experiment Validation: In vitro ThT Assay55%
mentions🧫Tau ASO Therapy55%
mentions🧫Microglial TREM2 Agonist In Vivo Efficacy55%
mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia55%
mentions🧫Vascular Contribution to Alzheimer's Disease — Beyond A55%
mentions🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol55%
mentions🧫Viral Infections and Alzheimer's Disease — causal mecha55%
mentions🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera55%
mentions🧫AAV-LRRK2 IND-Enabling Study Design55%
mentions🧫AAV Serotype Comparison for LRRK2 Knockdown in PD55%
mentions🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back55%
mentions🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio55%
mentions🧫Computational Modeling of Alpha-Synuclein Propagation in PD55%
mentions🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation55%
mentions🧫Alpha-Synuclein Seed Amplification Assay Validation55%
mentions🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation55%
mentions🧫Antiviral Therapy Trial for Parkinson's Disease55%
mentions🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&55%
mentions🧫Axonal Transport Dysfunction Validation in Parkinson's 55%
mentions🧫cGAS-STING Pathway Validation Study in Parkinson's Dise55%
mentions🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 55%
mentions🧫Combination Therapy Sequencing in Parkinson's Disease55%
mentions🧫CRISPR Gene Correction Approaches for CBS/PSP55%
mentions🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa55%
mentions🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#55%
mentions🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i55%
mentions🧫Endocannabinoid System Dysfunction Validation in Parkinson&#55%
mentions🧫Epigenetic Dysregulation Validation in Parkinson's Dise55%
mentions🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De55%
mentions🧫Exercise-BDNF-Mitophagy Biomarker Study in PD55%
mentions🧫Ferroptosis Validation in Parkinson's Disease55%
mentions🧫GLP-1 Agonist Neuroprotection Mechanism in PD55%
mentions🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&55%
mentions🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me55%
mentions🧫Cytochrome Therapeutics55%
mentions🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson55%
mentions🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown55%
mentions🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design55%
mentions🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne55%
mentions🧫Macroautophagy Dysfunction in PD - Experiment Design55%
mentions🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P55%
mentions🧫Validation: Membrane-Nucleation in iPSC Neurons55%
mentions🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr55%
mentions🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 55%
mentions🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag55%
mentions🧫MLCS Quantification in Parkinson's Disease55%
mentions🧫Experiment: Multi-Ethnic PD GWAS55%
mentions🧫Multiscale Computational Modeling of Protein Aggregation Kin55%
mentions🧫Neural Oscillation Dysfunction Validation in Parkinson'55%
mentions🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise55%
mentions🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper55%
mentions🧫Non-Motor Symptom Progression in Parkinson's Disease — 55%
mentions🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#55%
mentions🧫Parkinson's Disease Subtype Classification — Precision 55%
mentions🧫Peroxisomal Dysfunction Validation in Parkinson's Disea55%
mentions🧫Peroxisome Dysfunction Validation in Parkinson's Diseas55%
mentions🧫Prodromal Parkinson's Disease Biomarker Development — E55%
mentions🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin55%
mentions🧫Purinergic Signaling Dysfunction Validation in Parkinson55%
mentions🧫Regulated Necrosis Validation Study in Parkinson's Dise55%
mentions🧫Sirtuin Dysfunction Validation in Parkinson's Disease55%
mentions🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D55%
mentions🧫Stress Granule Dysfunction Validation in Parkinson's Di55%
mentions🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&55%
mentions🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki55%
mentions🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim55%
related🧫Endothelial CD2AP knockdown effects on memory in male mice54%
related🧫SPP1-mediated microglial synaptic engulfment assay54%
related🧫CD2AP expression and cognitive decline in AD patients54%
related🧫Competing endogenous RNA (ceRNA) network construction54%
related🧫Neuroimmune modulation and Aβ clearance mechanisms54%
related🧫GWAS of plasma NfL in East Asian cohort54%
related🧫Bioinformatics analysis and hub gene identification54%
related🧫Network Pharmacology Analysis of Shared AD Targets54%
related🧫Cognitive impact of TDP-43 pathology in AD patients54%
related🧫Meta-analysis of LRP1 C766T polymorphism and Alzheimer'54%
related🧫GWAS of composite biomarker score54%
related🧫MRI Phenotyping Method Concordance in Serbian AD Cohort54%
related🧫HDAC4 inhibition and NHE6 expression mechanism study54%
related🧫Endothelin-1 receptor A antagonist rescue in male CD2AP mice54%
related🧫Endothelin-1 receptor A antagonist rescue experiment54%
related🧫Reelin treatment rescue via ApoER2 in CD2AP mutant mice54%
related🧫SPP1 upregulation in perivascular cells in AD mouse models54%
related🧫Amyloid plaque load analysis in triple-mutant mouse brains54%
related🧫Plasma ATN biomarkers across AD continuum in Chilean cohort54%
related🧫16S rRNA sequencing of gut microbiome in PH-PS treated mice54%
related🧫GWAS of plasma pTau217 in East Asian cohort54%
related🧫PH-PS treatment in 5×FAD Alzheimer's disease mice54%
related🧫SIRPα modulation in mouse models of Alzheimer's disease54%
related🧫Dairy intake and dementia risk in Malmö Diet and Cancer coho54%
related🧫Spp1 knockout prevents synaptic loss in AD mouse models54%
related🧫Creation and validation of 3xAD-ChAT-Cre mouse model54%
related🧫In vivo BBB transport of LPS-carrying bEVs54%
related🧫Real-world safety study of Lecanemab in Japanese AD patients54%
related🧫CHI3L1 variant association with AD progression in human pati54%
related🧫Diosmin cognitive rescue in APP/PS1 mice54%
related🧫GWAS of plasma pTau181 in East Asian cohort54%
related🧫Tet2 modulation in Aβ42-injured mouse hippocampal neurons54%
related🧫Behavioral assessment of APP/PSEN1/GD3S triple-mutant mice54%
related🧫Immunofluorescence analysis of cerebral microvascular densit54%
related🧫Cell-cell interaction analysis of perivascular-microglial cr54%
related🧫SAHA@LIPO-ANG2 therapeutic efficacy in 5xFAD mice54%
related🧫Adoptive transfer of TCRAβ-Tregs in AD mouse model54%
related🧫Chi3l1 deletion in APP/PS1 mouse model of Alzheimer's d54%
related🧫CD2AP downregulation in brain endothelial cells - memory fun54%
related🧫Transcriptomic profiling and differential expression analysi54%
related🧫AAV-mediated Tet2 modulation in 2×Tg-AD mice behavioral stud54%
related🧫Single-cell RNA sequencing of microglial states in AD hippoc54%
related🧫bEV-mediated synaptic pruning via C1q-C3 pathway54%
related🧫AhR agonist effects on NEP expression in N2a cells54%
related🧫AhR transcriptional regulation of NEP gene54%
related🧫GWAS of plasma GFAP in East Asian cohort54%
related🧫AhR agonist effects on NEP in APP/PS1 mice54%
related🧫Abeta-induced cell death and aggregation in GD3S-deficient n54%
related🧫bEV isolation and LPS quantification from human samples54%
related🧫Cerebral blood flow regulation in CD2AP mutant mice54%
related🧫Meta-analysis of physical activity interventions on cognitiv54%
related🧫Single-nucleus RNA-seq integration analysis54%
related🧫Generation of Aβ-specific Tregs using CRISPR-Cas954%
related🧫qPCR and western blot analysis of microvascular functional m54%
related🧫Reelin glycoprotein treatment rescue experiment54%
related🧫bEV extraction and analysis from mouse samples54%
related🧫KEEPS Continuation: Long-term effects of menopausal hormone 54%
related🧫Summary-based Mendelian randomization analysis54%
related🧫Anti-ASC antibody intracerebroventricular injection in APP/P54%
related🧫ASC antibody treatment in SH-SY5Y-APP695 cells54%
related🧫s:** - Test whether HCN1 knockout specifically in EC layer I54%
related🧫Proposed experiment from debate on Synaptic pruning by micro54%
related🧫Tet2 expression analysis in aged 2×Tg-AD mouse brains54%
related🧫Morphological characterization of microglial states in human54%
related🧫Microglial SIRPα expression in human Alzheimer's diseas54%
related🧫APOE4 association with TDP-43 pathology in AD54%
related🧫Microglial activation by bEVs via Piezo154%
related🧫Curcumin-Licorice Combination in D-galactose/Sodium Nitrite 54%
related🧫Cerebrovascular function analysis in CD2AP mutant mice54%
related🧫CD2AP loss association with cognitive decline in AD patients54%
related🧫TDP-43 pathology prevalence and distribution in AD cases54%
related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%
related🧫4R-Tau Targeting Therapies for PSP and CBS54%
related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi54%
related🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau54%
related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti54%
related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?54%
related🧫Animal Model Comparison for Neurodegenerative Disease Therap54%
related🧫Anti-Tau Immunotherapy Dosing Optimization54%
related🧫ApoE4 Function in Alzheimer's Disease54%
related🧫Experiment: Autoimmune Hypothesis Testing in AD54%
related🧫Autophagy Enhancement Drug Screening for Neurodegeneration54%
related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#54%
related🧫Blood-Based Biomarker Panel for Early AD Detection54%
related🧫tACS Connectivity Trial in Early Alzheimer's54%
related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%
related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 54%
related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M54%
related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera54%
related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera54%
related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa54%
related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation54%
related🧫Gap Junction Dysfunction Validation in Parkinson's Dise54%
related🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas54%
related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise54%
related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech54%
related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr54%
related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis54%
related🧫Mixed Pathology Effects on Parkinson's Disease Progress54%
related🧫Neural Stem Cell Therapy for Alzheimer's Disease54%
related🧫Normal Aging to Alzheimer's Disease Transition Trigger 54%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%
related🧫Prion Strain Diversity and Selective Vulnerability54%
related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease54%
related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#54%
related🧫Sex Differences in Alzheimer's Disease — mechanisms and54%
related🧫Sleep Disruption and Alzheimer's Disease — mechanism an54%
related🧫Traumatic Brain Injury and Alzheimer's Disease Relation54%
related🧫Experiment Validation: In vitro ThT Assay54%
related🧫Tau ASO Therapy54%
related🧫Microglial TREM2 Agonist In Vivo Efficacy54%
related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia54%
related🧫Vascular Contribution to Alzheimer's Disease — Beyond A54%
related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol54%
related🧫Viral Infections and Alzheimer's Disease — causal mecha54%
related🧫Longitudinal TLR2 reporter gene study in α-synuclein mice54%
related🧫iPSC-derived astrocyte-neuron co-culture mitochondrial trans54%
related🧫TLR expression in α-synuclein overexpressing mice54%
related🧫TLR expression analysis in Parkinson's disease patients54%
related🧫Dexamethasone treatment study in α-synuclein mice54%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera54%
related🧫AAV-LRRK2 IND-Enabling Study Design54%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD54%
related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back54%
related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio54%
related🧫Computational Modeling of Alpha-Synuclein Propagation in PD54%
related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation54%
related🧫Alpha-Synuclein Seed Amplification Assay Validation54%
related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation54%
related🧫Antiviral Therapy Trial for Parkinson's Disease54%
related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&54%
related🧫Axonal Transport Dysfunction Validation in Parkinson's 54%
related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise54%
related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 54%
related🧫Combination Therapy Sequencing in Parkinson's Disease54%
related🧫CRISPR Gene Correction Approaches for CBS/PSP54%
related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa54%
related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#54%
related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i54%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#54%
related🧫Epigenetic Dysregulation Validation in Parkinson's Dise54%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De54%
related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD54%
related🧫Ferroptosis Validation in Parkinson's Disease54%
related🧫GLP-1 Agonist Neuroprotection Mechanism in PD54%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&54%
related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me54%
related🧫Cytochrome Therapeutics54%
related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson54%
related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown54%
related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design54%
related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne54%
related🧫Macroautophagy Dysfunction in PD - Experiment Design54%
related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P54%
related🧫Validation: Membrane-Nucleation in iPSC Neurons54%
related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr54%
related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 54%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag54%
related🧫MLCS Quantification in Parkinson's Disease54%
related🧫Experiment: Multi-Ethnic PD GWAS54%
related🧫Multiscale Computational Modeling of Protein Aggregation Kin54%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'54%
related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise54%
related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper54%
related🧫Non-Motor Symptom Progression in Parkinson's Disease — 54%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#54%
related🧫Parkinson's Disease Subtype Classification — Precision 54%
related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea54%
related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas54%
related🧫Prodromal Parkinson's Disease Biomarker Development — E54%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin54%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson54%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise54%
related🧫Sirtuin Dysfunction Validation in Parkinson's Disease54%
related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D54%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di54%
related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&54%
related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki54%
related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim54%
mentions🧪HSP90-Tau Disaggregation Complex Enhancement50%
mentions🧪VCP-Mediated Autophagy Enhancement50%
mentions🧪LRP1-Dependent Tau Uptake Disruption50%
mentions🧪Extracellular Vesicle Biogenesis Modulation50%
mentions🧪Synaptic Vesicle Tau Capture Inhibition50%
mentions🧪Trans-Synaptic Adhesion Molecule Modulation50%
mentions🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%
mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer50%
mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides50%
mentions🧪Competitive APOE4 Domain Stabilization Peptides50%
mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination50%
mentions🧪TREM2-mediated microglial tau clearance enhancement50%
mentions🧪Palmitoylation-Targeted BACE1 Trafficking Disruptors50%
mentions🧪APOE Isoform Conversion Therapy50%
mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%
mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%
mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%
mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy50%
mentions🧪APOE-TREM2 Interaction Modulation50%
mentions🧪TREM2-Mediated Selective Aggregate Clearance Pathway50%
mentions🧪TREM2-Dependent Microglial Senescence Transition50%
related🔬What are the mechanisms underlying blood-brain barrier trans50%
related🔬What are the mechanisms underlying apoe4 structural biology 50%
related🔬What are the mechanisms underlying synaptic pruning by micro50%
related🔬Analyze circuit-level changes in neurodegeneration using All50%
related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%
related🔬Investigate prion-like spreading of tau pathology through co50%
related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%
related🔬The disease-associated microglia (DAM) phenotype involves TR50%
related🔬What are the mechanisms underlying blood-brain barrier trans50%
related🔬What are the mechanisms underlying apoe4 structural biology 50%
related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬What are the mechanisms underlying protein aggregation cross50%
related🔬What are the mechanisms underlying synaptic pruning by micro50%
related🔬Analyze circuit-level changes in neurodegeneration using All50%
related🔬The disease-associated microglia (DAM) phenotype involves TR50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬Comprehensive analysis of immune cell subtypes in neurodegen50%
related🔬What cell types are most vulnerable in Alzheimers Disease ba50%
related🔬What cell types are most vulnerable in Alzheimer's Dise50%
related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%
related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%
related🔬Investigate prion-like spreading of tau pathology through co50%
related🔬How does metabolic reprogramming (glucose metabolism shifts,50%
related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%
related🔬What are the most promising therapeutic strategies for targe50%
related🔬How to break the GBA-alpha-synuclein bidirectional loop for 50%
related🔬Can gut-brain axis modulation prevent or slow Alzheimer'50%
related🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph50%
related🧪Metabolic Circuit Breaker via Lipid Droplet Modulation50%
related🧪Metabolic Switch Targeting for A1→A2 Repolarization50%
see_also📖SLC16A1 — Solute Carrier Family 16 Member 1 (Monocarboxylate50%
see_also📖C1QA Gene50%
see_also📖slc17a7 Gene50%
see_also📖Agitation in Alzheimer's Disease50%
see_also📖Alzheimer's Disease50%
see_also📖Alzheimer's Disease Genetic Variants50%
see_also📖APP Mutations in Alzheimer's Disease50%
see_also📖DLB, Parkinson's Disease, and Alzheimer's Disease:50%
see_also📖Early-Onset Alzheimer's Disease (EOAD)50%
see_also📖Investment Landscape: Alzheimer's Disease50%
see_also📖Preclinical Alzheimer's Disease50%
see_also📖Prodromal Alzheimer's Disease50%
see_also📖PSEN1 Mutations in Alzheimer's Disease50%
see_also📖PSEN2 Mutations in Alzheimer's Disease50%
see_also📖Sporadic vs Familial Alzheimer's Disease: Comprehensive50%
see_also📖TREM2 Variants in Alzheimer's Disease50%
see_also📖CHMP4B — Charged Multivesicular Body Protein 4B50%
see_also📖SST Gene50%
see_also📖HSP90AA1 Gene50%
see_also📖PVALB Gene - Parvalbumin50%
mentions🧫Multi-omics analysis of myricanol effects on gene expression44%
mentions🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc40%
mentions🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc40%
mentions🔬What cell types are most vulnerable in Alzheimer's Dise40%
mentions🔬What are the most promising therapeutic strategies for targe40%
mentions🔬Can gut-brain axis modulation prevent or slow Alzheimer'40%
mentions🔬What cell types are most vulnerable in Alzheimers Disease ba40%
mentions🔬How to break the GBA-alpha-synuclein bidirectional loop for 40%
mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%
mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen40%
mentions🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph40%
mentions🔬What are the mechanisms underlying autophagy-lysosome pathwa40%
mentions🔬What are the mechanisms underlying protein aggregation cross40%
mentions🔬How does metabolic reprogramming (glucose metabolism shifts,40%
mentions🔬What are the mechanisms underlying what are the mechanisms b40%
mentions🔬What are the mechanisms underlying what are the mechanisms b40%
related🧪TREM2 Conformational Stabilizers for Synaptic Discrimination40%
related🧪HSP90-Tau Disaggregation Complex Enhancement40%
related🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer40%
related🧪VCP-Mediated Autophagy Enhancement40%
related🧪LRP1-Dependent Tau Uptake Disruption40%
related🧪Extracellular Vesicle Biogenesis Modulation40%
related🧪Synaptic Vesicle Tau Capture Inhibition40%
related🧪TREM2-mediated microglial tau clearance enhancement40%
related🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides40%
related🧪Competitive APOE4 Domain Stabilization Peptides40%
related🧪Trans-Synaptic Adhesion Molecule Modulation40%
related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia40%
related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation40%
related🧪Complement C1QA Spatial Gradient in Cortical Layers40%
related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation40%
related🧪APOE Isoform Expression Across Glial Subtypes40%
SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub